SymbioCellTech Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • SymbioCellTech's estimated annual revenue is currently $775k per year.(i)
  • SymbioCellTech's estimated revenue per employee is $155,000

Employee Data

  • SymbioCellTech has 5 Employees.(i)
  • SymbioCellTech grew their employee count by -29% last year.

SymbioCellTech's People

NameTitleEmail/Phone
1
Founder & CEOReveal Email/Phone
2
Chief Scientific OfficerReveal Email/Phone
3
Chief Operating OfficerReveal Email/Phone
4
ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.8M5-17%N/AN/A
#2
$1.4M9-10%N/AN/A
#3
$5.9M3841%N/AN/A
#4
$1.1M7-53%N/AN/A
#5
$1.6M1011%N/AN/A
#6
$21.2M13710%N/AN/A
#7
$1.6M33-48%$17.8MN/A
#8
$1.9M120%N/AN/A
#9
$3.7M249%N/AN/A
#10
$0.9M60%N/AN/A
Add Company

What Is SymbioCellTech?

SymbioCellTech (SCT) is an early stage, university spin out, that has developed stem cell-based technology that achieves euglycemia (glucose control) in Type-1 Diabetes, and will soon be adapted for Type-2 Diabetes. The SCT proprietary Neo-Iset therapy, comprising both pancreatic islet and mesenchymal stem cells, can be administered in a simple out-patient procedure resulting in glucose control identical to that of a normal healthy individual. Backed by rigorous NIH, VA and privately funded research and resultant data, SCT has completed pre-clinical trials and is preparing for FDA submission and approval to begin well-designed, controlled, clinical trials treating humans suffering from Type-1 Diabetes. FDA Investigational New Animal Drug (INAD) approval for diabetic companion animals has been approved and canine clinical trials are ongoing with outstanding results and outcomes.

keywords:N/A

N/A

Total Funding

5

Number of Employees

$775k

Revenue (est)

-29%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.8M5-17%N/A
#2
$0.5M5-17%N/A
#3
$0.4M5-17%N/A
#4
$15M5-37%N/A
#5
$0.4M5-17%N/A